rs797044746
Variant summary
Our verdict is Pathogenic. The variant received 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000169.3(GLA):c.704C>G(p.Ser235Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S235Y) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 19 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
not provided Pathogenic:1
- -
Fabry disease Pathogenic:1
Variant summary: GLA c.704C>G (p.Ser235Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183490 control chromosomes. c.704C>G has been observed in individual(s) affected with Fabry Disease (example:Topaloglu_1999, Benjamin_2009, Saito_2013). These data indicate that the variant may be associated with disease. At least one publication reported an in vitro study that this variant results in absent baseline enzyme activity in transfected HEK293 cells (Wu_HM_2011). The following publications have been ascertained in the context of this evaluation (PMID: 19387866, 33915609, 20139917, 10666480, 21598360). ClinVar contains an entry for this variant (Variation ID: 197637). Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Cardiovascular phenotype Pathogenic:1
The p.S235C variant (also known as c.704C>G), located in coding exon 5 of the GLA gene, results from a C to G substitution at nucleotide position 704. The serine at codon 235 is replaced by cysteine, an amino acid with dissimilar properties. This variant has been detected in an individual reported to have classic Fabry disease phenotype with low alpha-galactosidase A enzyme activity (Topaloglu AK et al. Mol. Med., 1999 Dec;5:806-11), and in an individual with late-onset phenotype with reduced enzyme activity in patient-derived cell lines; however, reports may overlap (Benjamin ER et al. J. Inherit. Metab. Dis., 2009 Jun;32:424-40). In addition, an in vitro study indicated this variant to result in absent baseline enzyme activity in transfected HEK293 cells (Wu X et al. Hum. Mutat., 2011 Aug;32:965-77). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at